Clinical Trials
25 trialsNCT06802835 2026-05-11
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07524413 2026-04-13
Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06457503 2026-04-06
TRANSPARENT
Coherus Oncology, Inc.
Phase 4 Recruiting
NCT07385079 2026-02-03
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07373990 2026-01-28
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT05305131 2025-09-23
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
National University Hospital, Singapore
Phase 2 Recruiting
NCT06749899 2025-05-22
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 3 Recruiting
NCT06892431 2025-03-25
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT03924986 2025-01-31
RATIONALE-309
BeiGene
Phase 3 Completed
NCT05587374 2025-01-23
GEMSTONE
Sun Yat-sen University
Phase 3 Active not recruiting
NCT03840421 2025-01-13
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT06611826 2024-09-25
GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06019130 2024-05-16
NPC-Nivo
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 2 Recruiting
NCT02611960 2023-07-13
Keynote-122
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03700476 2023-03-28
CONTINUUM
Sun Yat-sen University
Phase 3 Unknown
NCT00370890 2022-02-17
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Chinese University of Hong Kong
Phase 3 Completed
NCT05198531 2022-01-21
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT01528618 2021-10-04
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT02627807 2020-06-16
Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase NA Unknown
NCT00603915 2019-02-28
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT03619824 2018-10-09
PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT00003182 2013-12-04
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00004097 2013-09-20
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00305734 2013-01-25
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00436800 2009-09-18
Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Sanofi
Phase 2 Completed